Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30202366 | 0.82 | CYP2A6 (0.30) | — | |
| SCHEMBL20154935 | 0.82 | TSHR (0.31) | — | |
| SCHEMBL2742986 | 0.80 | — | — | |
| SCHEMBL21737018 | 0.80 | — | — | |
| SCHEMBL27319066 | 0.80 | — | — | |
| SCHEMBL9900250 | 0.80 | NOS3 (0.36) | — | |
| SCHEMBL16431582 | 0.80 | — | — | |
| SCHEMBL29427912 | 0.80 | NOS3 (0.36) | — | |
| SCHEMBL2742982 | 0.80 | CCNB2 (0.30) | — | |
| SCHEMBL26023870 | 0.80 | PIK3CG (0.31) | PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685778-B | Method for synthesizing long-circulating cationic liposome | 苏州艾博生物科技有限公司 | 2023-10-17 | — | — | CN | claimed |
| CN-114685778-A | Synthesis method of long-circulating cationic liposome | 苏州艾博生物科技有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-20220135613-A1 | METHOD FOR PREPARING DRUG TOXIN PNU-159682 FOR ANTIBODY DRUG CONJUGATE, AND INTERMEDIATES THEREIN | LEVENA BIOPHARMA CO LTD (CN) | 2022-05-05 | — | — | US | claimed |
| EP-3907223-A1 | METHOD FOR PREPARING DRUG TOXIN PNU-159682 OF ANTIBODY DRUG CONJUGATE, AND INTERMEDIATE THEREIN | Levena Biopharma Co., Ltd. (CN) | 2021-11-10 | — | — | EP | claimed |
| CN-110776501-B | Preparation method of drug toxin PNU-159682 for antibody drug conjugate and intermediate thereof | 联宁（苏州）生物制药有限公司 | 2021-04-02 | — | — | CN | claimed |
| WO-2021031599-A1 | METHOD FOR PREPARING DRUG TOXIN PNU-159682 OF ANTIBODY DRUG CONJUGATE, AND INTERMEDIATE THEREIN | 联宁（苏州）生物制药有限公司 | 2021-02-25 | — | — | WO | claimed |
| CN-110776501-A | Preparation method of drug toxin PNU-159682 for antibody drug conjugate and intermediate thereof | 联宁（苏州）生物制药有限公司 | 2020-02-11 | — | — | CN | claimed |
| US-7316826-B2 | Coffee aroma with improved stability | SYMRISE GMBH & CO. KG (DE) | 2008-01-08 | — | — | US | claimed |
| US-20040202767-A1 | Coffee aroma with improved stability | SYMRISE AG (DE) | 2004-10-14 | — | — | US | claimed |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| US-20230340055-A1 | GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2023-10-26 | — | — | US | disclosed |
| EP-1329495-A2 | Gas odorization | HAARMANN & REIMER GMBH (DE) | 2003-07-23 | — | — | EP | disclosed |
| EP-1109881-B1 | GAS ODORIZATION METHOD | HAARMANN & REIMER GMBH (DE) | 2003-03-05 | — | — | EP | disclosed |
| EP-1109881-A1 | GAS ODORIZATION METHOD | HAARMANN & REIMER GMBH (DE) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000011120-A1 | GAS ODORIZATION METHOD | HAARMANN & REIMER GMBH (DE) | 2000-03-02 | — | — | WO | disclosed |
| EP-0619317-A1 | An expeditious synthesis of C-disaccharides using a temporary ketal connection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1994-10-12 | — | — | EP | disclosed |
| EP-0309203-A2 | Flavorant-release additives and compositions containing them | Philip Morris Products Inc. (US) | 1989-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340055-A1 | GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF | IL2, IL1A, ILF2 | PIK3CG 4687/4885 |
| US-20220135613-A1 | METHOD FOR PREPARING DRUG TOXIN PNU-159682 FOR ANTIBODY DRUG CONJUGATE, AND INTERMEDIATES THEREIN | ANTXR2, TNNT2, SLC47A2 | PIK3CG 3619/4885 |
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | PIK3CG 1378/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | PIK3CG 1426/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | PIK3CG 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.